MaltSci 麦伴科研

Appearance

Popular Reports / hepatology

This report is written by MaltSci based on the latest literature and research findings

How does non-alcoholic fatty liver disease develop? ​

Abstract ​

Non-alcoholic fatty liver disease (NAFLD) has become a major global health issue, characterized by the accumulation of fat in the liver without excessive alcohol consumption. This condition ranges from simple steatosis to more severe forms such as non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer. The increasing prevalence of NAFLD is closely linked to rising obesity rates and metabolic syndrome, emphasizing the need for research and public health initiatives. The development of NAFLD is multifactorial, involving complex interactions between genetic predispositions, environmental factors, and metabolic dysfunctions, with insulin resistance playing a central role in its pathogenesis. Additionally, factors such as gut microbiota, oxidative stress, and immune responses are critical in the disease's progression. Lifestyle factors, including dietary patterns and physical activity, significantly influence the risk and progression of NAFLD. Recent advances in understanding the genetic and epigenetic modifications related to NAFLD have opened new avenues for research. This review synthesizes current findings on the pathophysiological mechanisms underlying NAFLD, including insulin resistance, inflammation, and the role of the gut-liver axis, while also discussing current and emerging therapeutic approaches. Understanding these intricacies is crucial for developing effective prevention and treatment strategies to manage this increasingly prevalent liver disease.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Pathophysiology of NAFLD
    • 2.1 Insulin Resistance and Lipid Accumulation
    • 2.2 Role of Inflammation in NAFLD Progression
    • 2.3 Genetic and Epigenetic Factors
  • 3 Environmental and Lifestyle Factors
    • 3.1 Dietary Influences on NAFLD Development
    • 3.2 Physical Activity and Its Protective Role
    • 3.3 The Impact of Obesity
  • 4 Gut Microbiota and NAFLD
    • 4.1 Dysbiosis and Its Role in Liver Disease
    • 4.2 Mechanisms of Gut-Liver Axis Interaction
  • 5 Hormonal Changes and NAFLD
    • 5.1 The Role of Adipokines
    • 5.2 Hormonal Regulation of Lipid Metabolism
  • 6 Current and Emerging Therapeutic Approaches
    • 6.1 Lifestyle Interventions
    • 6.2 Pharmacological Treatments
    • 6.3 Future Directions in NAFLD Management
  • 7 Summary

1 Introduction ​

Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant global health concern, affecting millions of individuals worldwide. This condition is characterized by the accumulation of fat in the liver without excessive alcohol consumption, and it encompasses a spectrum of liver disorders, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer [1]. The rising prevalence of NAFLD correlates closely with the increasing rates of obesity and metabolic syndrome, making it a critical focus of research and public health initiatives [2][3].

The development of NAFLD is multifactorial, involving complex interactions between genetic predispositions, environmental factors, and metabolic dysfunctions. Insulin resistance is often cited as a central mechanism in the pathogenesis of NAFLD, leading to increased lipid accumulation in hepatocytes and subsequent inflammation [4][5]. The role of the gut microbiota, oxidative stress, and immune responses are also critical in the progression from simple steatosis to more severe forms of the disease [3][6]. As NAFLD progresses, it can lead to significant liver damage, making it imperative to understand the underlying mechanisms to develop effective prevention and treatment strategies [1].

Research in this field has evolved significantly over the past decades, highlighting the importance of both lifestyle and genetic factors in NAFLD development. Studies have demonstrated that dietary patterns, physical activity, and obesity play pivotal roles in modulating the risk and progression of NAFLD [5][7]. Furthermore, emerging insights into epigenetic modifications and their impact on gene expression have opened new avenues for understanding the disease [8].

This review aims to elucidate the pathophysiological mechanisms underlying the development of NAFLD, focusing on several key areas. First, we will explore the pathophysiology of NAFLD, including the roles of insulin resistance, lipid metabolism disturbances, and inflammatory processes. Next, we will examine the environmental and lifestyle factors that contribute to NAFLD, such as dietary influences, physical activity, and obesity. The review will also delve into the role of gut microbiota and hormonal changes in NAFLD progression. Finally, we will discuss current and emerging therapeutic approaches, including lifestyle interventions and pharmacological treatments, that hold promise for managing this increasingly prevalent liver disease.

By synthesizing current research findings, this report will provide a comprehensive overview of how NAFLD develops and progresses, highlighting potential therapeutic targets and preventive strategies. Understanding the intricacies of NAFLD development is crucial for advancing clinical practices and improving patient outcomes in the context of this significant public health issue.

2 Pathophysiology of NAFLD ​

2.1 Insulin Resistance and Lipid Accumulation ​

Non-alcoholic fatty liver disease (NAFLD) is a complex condition characterized by the accumulation of fat in the liver, which is not attributable to alcohol consumption. The development of NAFLD is closely linked to insulin resistance, a key factor in the metabolic syndrome, which encompasses a range of disorders including type 2 diabetes, obesity, and dyslipidemia.

Insulin resistance is fundamentally a state where the body's cells become less responsive to insulin, a hormone crucial for glucose and lipid metabolism. In individuals with NAFLD, this resistance leads to several metabolic abnormalities. Specifically, insulin resistance results in increased peripheral lipolysis, enhanced hepatic glucose output due to increased gluconeogenesis, and augmented lipid oxidation. These changes contribute to a state of oxidative stress in the liver, further exacerbating the condition (Haque and Sanyal, 2002; Parekh and Anania, 2007) [9][10].

The accumulation of ectopic lipids, particularly diacylglycerols and ceramides, plays a pivotal role in the pathophysiology of insulin resistance associated with NAFLD. These lipids interfere with insulin signaling pathways, leading to impaired glucose uptake and increased hepatic fat accumulation. The inflammatory response, driven by cytokines and adipokines released from adipose tissue, further complicates the situation by modulating insulin sensitivity and promoting lipid accumulation in the liver (Asrih and Jornayvaz, 2013; Liu et al., 2010) [11][12].

Moreover, the interplay between excessive caloric intake, visceral obesity, and genetic predispositions can initiate and perpetuate the cycle of insulin resistance and hepatic fat accumulation. As insulin resistance progresses, the liver's ability to process fats diminishes, leading to an increase in free fatty acids (FFAs) in the bloodstream. This exacerbates mitochondrial dysfunction and contributes to lipotoxicity, ultimately resulting in the progression from simple steatosis to more severe forms of liver disease, including nonalcoholic steatohepatitis (NASH), fibrosis, and potentially cirrhosis (Gaggini et al., 2013; Bugianesi et al., 2004) [13][14].

In summary, the development of NAFLD is a multifactorial process primarily driven by insulin resistance, which leads to ectopic lipid accumulation and subsequent liver inflammation. This condition serves as a hepatic manifestation of the metabolic syndrome, emphasizing the need for comprehensive approaches in both prevention and treatment that address the underlying metabolic disturbances.

2.2 Role of Inflammation in NAFLD Progression ​

Non-alcoholic fatty liver disease (NAFLD) is a complex and heterogeneous disorder characterized by the accumulation of fat in the liver, and it encompasses a spectrum of liver conditions ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and potentially hepatocellular carcinoma (HCC). The pathophysiology of NAFLD is closely linked to metabolic syndrome, which includes conditions such as obesity, insulin resistance, and type 2 diabetes, and is increasingly recognized as a significant public health concern due to its rising prevalence globally.

Inflammation plays a crucial role in the progression of NAFLD, particularly in the transition from simple steatosis to NASH. The inflammatory processes in NAFLD are initiated by various factors, including lipid overload, oxidative stress, and gut-liver axis dysregulation. These factors trigger the activation of the innate immune system, leading to a cascade of inflammatory responses that contribute to liver injury and disease progression.

Key immune cells involved in the inflammatory response during NAFLD include macrophages, T cells, and other innate immune cells. Liver macrophages, which consist of resident Kupffer cells and infiltrating monocytes, are pivotal in maintaining liver homeostasis and regulating inflammation. In the context of NAFLD, these macrophages become activated and promote inflammation and fibrosis as the disease progresses towards NASH [15]. Furthermore, T cells, particularly subsets such as Th17 cells, have been implicated in driving inflammation in NAFLD, contributing to the transition to more severe forms of liver disease [16].

The inflammatory response in NAFLD is characterized by the accumulation of leukocytes and the release of pro-inflammatory cytokines and chemokines, which exacerbate tissue injury. This chronic low-grade inflammation not only contributes to hepatocyte apoptosis but also activates hepatic stellate cells, leading to fibrosis [17]. The interaction between inflammatory mediators and various immune cells creates a feedback loop that perpetuates liver inflammation and damage [18].

Moreover, recent studies have highlighted the role of extracellular vesicles (EVs) derived from immune cells and hepatocytes in mediating liver inflammation during NASH. These EVs carry bioactive molecules that can influence the inflammatory environment, thereby playing a significant role in the progression of NAFLD [19].

The gut-liver axis also plays a critical role in the inflammatory processes associated with NAFLD. Dysbiosis, or an imbalance in gut microbiota, can lead to increased intestinal permeability and the translocation of microbial antigens into the liver, further fueling the inflammatory response [20]. This interplay between the gut microbiome and liver inflammation is an area of active research, as it may provide new therapeutic targets for managing NAFLD.

In summary, the development and progression of NAFLD are intricately linked to inflammatory processes. Chronic inflammation driven by metabolic dysregulation, immune cell activation, and gut-liver interactions significantly contributes to the transition from simple steatosis to more severe liver conditions, highlighting the importance of targeting inflammation in therapeutic strategies for NAFLD [15][17][21].

2.3 Genetic and Epigenetic Factors ​

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial condition characterized by the accumulation of excess fat in liver cells, which is not attributed to alcohol consumption. The pathophysiology of NAFLD involves a complex interplay of genetic and epigenetic factors, along with environmental influences, leading to the disease's initiation and progression.

Genetic predisposition plays a significant role in NAFLD development. Several genetic polymorphisms have been identified that are associated with the disease's susceptibility, including variants in genes such as PNPLA3, TM6SF2, MBOAT7, and GCKR. These genetic variations influence lipid metabolism, insulin sensitivity, and overall liver function, contributing to the accumulation of triglycerides in the liver and the progression to more severe forms of the disease, such as non-alcoholic steatohepatitis (NASH) and fibrosis [22][23][24].

In addition to genetic factors, epigenetic modifications are crucial in the pathogenesis of NAFLD. Epigenetics refers to heritable changes in gene expression that do not involve alterations to the underlying DNA sequence. Key epigenetic mechanisms implicated in NAFLD include DNA methylation, histone modifications, and the regulation by non-coding RNAs. These modifications can affect the expression of genes involved in lipid metabolism, inflammation, and oxidative stress, thereby influencing the disease's progression [25][26][27].

The interaction between genetic susceptibility and environmental factors, such as diet and physical activity, is particularly significant. A high-calorie, high-fat diet can lead to epigenetic changes that promote NAFLD, highlighting the importance of lifestyle in managing the disease [8][28]. For instance, the polygenic risk score, which aggregates multiple genetic risk factors, has been associated with NAFLD outcomes, suggesting that dietary context can modulate the effects of genetic predisposition [22].

Moreover, environmental triggers, including obesity, insulin resistance, and sedentary lifestyle, can exacerbate the genetic risk, leading to the clinical manifestations of NAFLD. These interactions illustrate the complexity of NAFLD's pathophysiology, where genetic and epigenetic factors converge with lifestyle choices to influence disease onset and progression [29][30].

Understanding the genetic and epigenetic mechanisms underlying NAFLD is essential for developing targeted therapeutic strategies and personalized treatment approaches, which may improve disease management and patient outcomes [31][32].

3 Environmental and Lifestyle Factors ​

3.1 Dietary Influences on NAFLD Development ​

Non-alcoholic fatty liver disease (NAFLD) is a complex condition characterized by the abnormal accumulation of fat in the liver, and its development is significantly influenced by various dietary factors. The pathogenesis of NAFLD involves a multifaceted interplay between genetic predispositions and environmental influences, particularly dietary habits.

Dietary composition plays a critical role in the onset and progression of NAFLD. High intake of simple carbohydrates, especially fructose, has been linked to the development of fatty liver. Excessive consumption of sugars can lead to increased de novo lipogenesis, resulting in lipid accumulation in hepatocytes. Conversely, non-digestible carbohydrates, such as dietary fiber, can positively affect gut microbiota and enhance gut barrier integrity, thereby reducing inflammation and the risk of NAFLD [33].

The quality of dietary fats also significantly impacts NAFLD. Diets high in saturated fats have been associated with the exacerbation of liver conditions, while unsaturated fats may offer protective effects. Moreover, the overall caloric intake is crucial; caloric surplus can contribute to obesity and insulin resistance, both of which are major risk factors for NAFLD [22].

In addition to macronutrients, micronutrients also play a role in NAFLD development. For instance, antioxidants and certain vitamins can mitigate oxidative stress, a key factor in the progression of NAFLD to more severe forms such as non-alcoholic steatohepatitis (NASH) [34]. Furthermore, the intake of omega-3 fatty acids has been suggested to have beneficial effects on liver health by reducing inflammation and improving lipid profiles [35].

The interaction between diet and gut microbiota is another crucial aspect in the development of NAFLD. Dysbiosis, or an imbalance in gut microbiota, can influence metabolic pathways and contribute to liver disease. Certain dietary patterns may exacerbate dysbiosis, leading to increased intestinal permeability and subsequent hepatic inflammation [36].

Environmental pollutants, including endocrine-disrupting chemicals, may also interact with dietary factors to influence NAFLD development. These pollutants can disrupt metabolic processes and exacerbate the effects of an unhealthy diet, potentially leading to a higher risk of liver disease [35].

In summary, the development of NAFLD is intricately linked to dietary influences, including the type and amount of macronutrients consumed, the presence of beneficial micronutrients, and the overall dietary pattern. A comprehensive understanding of these dietary factors is essential for developing effective prevention and treatment strategies for NAFLD, emphasizing the need for lifestyle modifications aimed at improving dietary habits.

3.2 Physical Activity and Its Protective Role ​

Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a significant public health issue, with its development closely linked to various environmental and lifestyle factors. The primary contributors to the onset of NAFLD include excessive caloric intake, physical inactivity, and dietary habits, all of which have been implicated in the disease's pathogenesis.

The association between lifestyle factors and the development of NAFLD is well-established. Modern lifestyles characterized by high caloric intake and reduced physical activity have contributed to the rising prevalence of this condition. Specifically, the lack of physical exercise exacerbates the accumulation of hepatic fat, which is a hallmark of NAFLD. Lifestyle modifications, particularly those focusing on increased physical activity, have shown promise in improving hepatic steatosis and liver histology in affected individuals (Hallsworth & Adams, 2019) [37].

Physical activity plays a critical protective role against NAFLD. Studies indicate that high levels of physical activity and improved cardiorespiratory fitness can significantly reduce the risk of developing NAFLD. For instance, research has demonstrated that maintaining over 60 minutes of vigorous physical activity per week correlates with a 42% reduction in the odds of NAFLD (Kerr et al., 2021) [38]. Moreover, the relationship between physical activity intensity and NAFLD suggests that not only the quantity but also the quality of exercise is vital for liver health. Engaging in moderate to vigorous physical activity has been shown to produce beneficial effects on liver fat content and associated metabolic parameters, independent of weight loss (Johnson & George, 2010) [39].

The underlying mechanisms through which physical activity exerts its protective effects against NAFLD include improvements in mitochondrial function and modulation of epigenetic factors. Exercise has been shown to enhance mitochondrial metabolism in the liver, thereby facilitating better lipid oxidation and reducing hepatic fat accumulation (Stevanović et al., 2020) [40]. Additionally, the impact of exercise extends beyond immediate physiological changes; it may also influence transgenerational phenotypes, thereby affecting the risk of NAFLD in offspring (Stevanović et al., 2020) [40].

Furthermore, dietary habits, particularly the consumption of high-glycemic index foods and simple carbohydrates, have been linked to the pathogenesis of NAFLD. These dietary components can lead to increased hepatic fat deposition and inflammation, thereby aggravating the disease (Lê & Bortolotti, 2008) [41]. Consequently, lifestyle interventions that encompass both dietary modifications and increased physical activity are recommended as first-line treatments for NAFLD, aiming to reduce liver fat and improve overall liver function (Zelber-Sagi et al., 2016) [42].

In conclusion, the development of NAFLD is intricately linked to lifestyle factors, particularly physical inactivity and poor dietary choices. Increasing physical activity emerges as a crucial strategy for the prevention and management of NAFLD, highlighting the importance of lifestyle modifications in mitigating this growing health concern.

3.3 The Impact of Obesity ​

Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant global health issue, particularly in the context of rising obesity rates and associated metabolic disorders. The development of NAFLD is closely linked to various environmental and lifestyle factors, with obesity being the most significant risk factor.

Obesity contributes to the onset of NAFLD through several mechanisms. The condition arises when there is an imbalance between the uptake and synthesis of fatty acids in the liver and their oxidation and export as triglycerides. This imbalance is primarily driven by insulin resistance, which is a common feature of obesity. Insulin resistance leads to increased lipolysis and free fatty acid delivery to the liver, resulting in excessive fat accumulation. Furthermore, the pathogenesis of NAFLD is exacerbated by lipotoxicity, oxidative stress, and chronic inflammation, all of which are associated with obesity[43].

In addition to obesity, other lifestyle factors play a crucial role in the development of NAFLD. Excessive caloric intake, particularly from high-glycemic index foods and simple carbohydrates like fructose, has been shown to stimulate hepatic de novo lipogenesis while decreasing lipid oxidation. This dietary pattern leads to increased fat deposition in the liver, contributing to the progression of NAFLD[41]. Furthermore, reduced physical activity and sedentary behavior further compound the risk, as they contribute to weight gain and the associated metabolic disturbances[37].

Environmental factors, including exposure to endocrine-disrupting chemicals (EDCs), have also been implicated in the development of NAFLD. These chemicals can interfere with metabolic processes and may exacerbate obesity-related conditions. For instance, EDCs can disrupt hormonal regulation and promote insulin resistance, thereby influencing the risk of developing NAFLD[44]. The liver accumulates various lipophilic EDCs, which can exacerbate inflammation and contribute to the pathogenesis of NAFLD[45].

Genetic predispositions also play a role in the development of NAFLD. Genome-wide association studies have identified specific genetic mutations that increase susceptibility to steatosis, further complicating the interaction between genetic and environmental factors in the disease's etiology[46].

In summary, the development of non-alcoholic fatty liver disease is a multifactorial process heavily influenced by obesity, lifestyle choices, environmental exposures, and genetic factors. The interplay of these elements underscores the importance of a comprehensive approach to prevention and management, focusing on lifestyle modifications, dietary interventions, and awareness of environmental risks.

4 Gut Microbiota and NAFLD ​

4.1 Dysbiosis and Its Role in Liver Disease ​

Non-alcoholic fatty liver disease (NAFLD) is a complex and multifactorial condition characterized by excessive fat accumulation in the liver without significant alcohol consumption. The pathogenesis of NAFLD involves a variety of mechanisms, among which the gut microbiota and its dysbiosis play a crucial role.

Dysbiosis refers to an imbalance in the gut microbiota composition, which can be triggered by various factors, including dietary habits, obesity, and environmental influences. This imbalance is commonly observed in patients with NAFLD and is associated with impaired intestinal permeability. Dysbiosis leads to the translocation of harmful bacterial products, such as lipopolysaccharides (LPS), short-chain fatty acids (SCFAs), and other metabolites into the portal circulation, ultimately affecting liver function [47].

The gut-liver axis is a critical pathway that links the gut microbiota to liver health. Altered gut microbiota can influence liver metabolism and promote hepatic inflammation and steatosis, contributing to the progression of NAFLD. For instance, high-fat diets are known to induce dysbiosis, which alters microbial metabolic activities and enhances liver inflammation. Specific metabolites produced by gut microbiota, such as saturated fatty acids, can activate liver macrophages and increase the expression of pro-inflammatory cytokines like TNF-α, thereby advancing the progression from simple steatosis to non-alcoholic steatohepatitis (NASH) [47].

Furthermore, dysbiosis is linked to increased intestinal permeability, leading to endotoxemia, where LPS enters the bloodstream and triggers inflammatory responses in the liver. This chronic inflammation is a key factor in the progression of NAFLD to more severe forms, including NASH and eventually liver fibrosis or cirrhosis [48].

Recent research has also highlighted the role of specific gut microbiota signatures associated with NAFLD. For example, changes in the abundance of certain bacterial species can disrupt bile acid metabolism and short-chain fatty acid production, both of which are essential for maintaining liver health [49]. Additionally, dietary factors, particularly those rich in saturated fats and sugars, can exacerbate dysbiosis, further promoting liver disease [50].

In summary, the development of NAFLD is closely linked to dysbiosis of the gut microbiota, which disrupts the gut-liver axis and contributes to liver inflammation, fat accumulation, and the progression of the disease. Understanding these mechanisms offers potential therapeutic targets for managing NAFLD, including dietary interventions and microbiota modulation strategies [51].

4.2 Mechanisms of Gut-Liver Axis Interaction ​

Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver disorder characterized by the accumulation of fat in the liver without significant alcohol consumption. The development of NAFLD is intricately linked to metabolic dysfunctions, and recent research highlights the crucial role of the gut-liver axis in its pathogenesis.

The gut-liver axis refers to the bidirectional communication between the gut and the liver, primarily mediated through the portal circulation, bile duct, and systemic circulation. Dysbiosis, or an imbalance in the gut microbiota, is increasingly recognized as a significant contributor to the development and progression of NAFLD. Alterations in the gut microbiome can lead to increased intestinal permeability, allowing for the translocation of microbial metabolites and toxins into the liver, which can trigger inflammation and hepatic steatosis [52][53].

Several mechanisms through which the gut-liver axis influences NAFLD have been identified:

  1. Microbial Metabolites: Gut microbiota produce various metabolites, such as short-chain fatty acids (SCFAs), bile acids, and lipopolysaccharides (LPS). SCFAs have anti-inflammatory properties and can improve insulin sensitivity, whereas LPS can promote inflammation and liver injury when they enter the systemic circulation [54][55].

  2. Alteration of Gut Barrier Function: Dysbiosis can compromise the intestinal barrier, leading to increased intestinal permeability. This allows for the passage of harmful substances into the liver, triggering inflammatory responses and contributing to hepatic lipid accumulation [53][56].

  3. Insulin Resistance: The gut microbiota can influence metabolic pathways that affect insulin sensitivity. For instance, dysbiosis is associated with the development of insulin resistance, which is a critical factor in the progression of NAFLD [57].

  4. Inflammatory Pathways: Gut-derived factors can activate inflammatory pathways in the liver. For example, the interaction of microbial products with toll-like receptors (TLRs) on liver cells can lead to the secretion of pro-inflammatory cytokines, exacerbating liver inflammation and contributing to the transition from simple steatosis to non-alcoholic steatohepatitis (NASH) [57][58].

  5. Neural Interactions: The gut-liver neural axis also plays a role in NAFLD progression. Modulation of neural signals between the gut and liver can affect hepatic metabolism and inflammation. For instance, studies have shown that targeting serotonin pathways can ameliorate fatty liver and fibrosis in NAFLD models [59].

  6. Nutritional Influences: Diet significantly impacts the gut microbiota composition and function. Diets high in fat and sugar can promote dysbiosis, whereas healthier dietary patterns, such as the Mediterranean diet, may support a beneficial microbiota profile, thereby protecting against NAFLD [57].

The intricate interplay between the gut microbiota and the liver underscores the importance of the gut-liver axis in the pathogenesis of NAFLD. Understanding these mechanisms not only enhances our knowledge of NAFLD development but also opens avenues for potential therapeutic strategies targeting gut microbiota modulation to prevent or treat this condition [60][61].

5 Hormonal Changes and NAFLD ​

5.1 The Role of Adipokines ​

Non-alcoholic fatty liver disease (NAFLD) is a complex condition characterized by the accumulation of excess fat in the liver in individuals who do not consume significant amounts of alcohol. The development of NAFLD is multifactorial, with hormonal changes and the role of adipokines being significant contributors to its pathogenesis.

The pathogenesis of NAFLD is often conceptualized through the "multiple-hit" hypothesis, which posits that the disease progresses through a series of interconnected events rather than a single causative factor. The initial "hit" involves the accumulation of liver fat, primarily due to insulin resistance, which is often exacerbated by obesity and metabolic syndrome. This fat accumulation is followed by a second hit characterized by necroinflammation and fibrosis, leading to more severe forms of liver disease, such as non-alcoholic steatohepatitis (NASH) [62].

Adipose tissue, recognized as an endocrine organ, plays a pivotal role in the development of NAFLD through the secretion of adipokines—bioactive substances that regulate lipid metabolism and inflammatory responses. Adipokines such as adiponectin and leptin have well-established roles in NAFLD pathophysiology. Adiponectin, known for its insulin-sensitizing properties, is typically found at lower levels in individuals with obesity and metabolic disorders, correlating with a pro-inflammatory state that contributes to NAFLD [63].

Leptin, another key adipokine, is produced in response to increased adiposity and acts as a pro-inflammatory stimulus when present in excess. Elevated levels of leptin have been associated with the progression of NAFLD, as they may enhance hepatic inflammation and insulin resistance [64]. Furthermore, other adipokines such as resistin and visfatin have been implicated in NAFLD, although their exact roles remain less clear and require further investigation [65].

In patients with HIV and HBV infections, the disruption of adipogenesis and the synthesis of adipokines further complicates the metabolic landscape, leading to an exacerbation of NAFLD. This interplay highlights the importance of the hepatokine/adipokine axis in mediating metabolic disturbances and inflammatory responses that drive the progression of NAFLD [66].

Recent studies emphasize the need for a deeper understanding of the relationship between hormonal changes, adipokine secretion, and the pathogenesis of NAFLD. Hormonal dysregulation, particularly involving sex hormones, also influences liver metabolism and the risk of developing NAFLD. For instance, androgen levels and their regulation through sex hormone-binding globulin (SHBG) have been suggested as potential factors in the pathophysiology of NAFLD, indicating a sex-specific mechanism in disease development [67].

Overall, the intricate interplay between hormonal changes, adipokine dysregulation, and metabolic dysfunction underscores the multifaceted nature of NAFLD development. Further research is warranted to elucidate the specific mechanisms by which these factors contribute to the disease, which may lead to novel therapeutic targets and biomarkers for managing NAFLD effectively.

5.2 Hormonal Regulation of Lipid Metabolism ​

Non-alcoholic fatty liver disease (NAFLD) is a complex and multifactorial condition characterized by the accumulation of fat in the liver in the absence of excessive alcohol consumption. The development of NAFLD is closely linked to various hormonal changes that significantly influence lipid metabolism. Hormonal regulation plays a critical role in the pathogenesis of NAFLD, particularly through the effects of insulin, sex hormones, and thyroid hormones.

Insulin resistance is a central feature of NAFLD, often associated with metabolic syndrome, obesity, and type 2 diabetes mellitus. Elevated insulin levels promote hepatic lipogenesis and inhibit fatty acid oxidation, leading to an excess accumulation of lipids in the liver. This dysregulation of lipid metabolism is exacerbated by the presence of hyperinsulinemia, which is frequently observed in patients with NAFLD [68].

Sex hormones also significantly impact the development of NAFLD, demonstrating a pronounced sexual dimorphism in disease prevalence and progression. In men, normal androgen levels are protective against hepatic fat accumulation, whereas androgen deficiency can lead to increased hepatic steatosis. Conversely, in women, higher androgen levels, particularly in conditions such as polycystic ovary syndrome (PCOS), may increase the risk of developing NAFLD [67]. Additionally, the role of sex hormone binding globulin (SHBG) has emerged as a potential marker for NAFLD, suggesting that androgen dysfunction may influence the disease's progression [67].

Thyroid hormones also contribute to the regulation of hepatic lipid metabolism. Subclinical hypothyroidism has been linked to alterations in lipid metabolism that promote fat accumulation in the liver. Thyroid-stimulating hormone (TSH) and follicle-stimulating hormone (FSH) may have additive effects on the development of NAFLD, indicating that even when peripheral hormone levels are within normal ranges, dysregulation at the level of stimulating hormones can impact liver metabolism [69].

The interplay between these hormonal changes and lipid metabolism is further complicated by the impact of circadian rhythms on metabolic processes. Disruptions in circadian patterns can lead to metabolic disturbances that exacerbate NAFLD [70]. Understanding these hormonal interactions is essential for identifying potential therapeutic targets and developing effective interventions for NAFLD.

In summary, the development of NAFLD is influenced by a complex interplay of hormonal changes that affect lipid metabolism. Insulin resistance, sex hormone levels, and thyroid hormone status are key factors that contribute to the pathogenesis of this disease. The recognition of these hormonal influences opens avenues for targeted therapies and better management of NAFLD in affected populations.

6 Current and Emerging Therapeutic Approaches ​

6.1 Lifestyle Interventions ​

Non-alcoholic fatty liver disease (NAFLD) develops through a complex interplay of metabolic factors, primarily associated with insulin resistance and the metabolic syndrome. The pathogenesis of NAFLD involves excessive hepatic lipogenesis and inadequate hepatic lipolysis, often exacerbated by factors such as obesity, type 2 diabetes, hypertension, and dyslipidemia. These metabolic derangements lead to the accumulation of fat in the liver, which can progress from simple steatosis to more severe forms like non-alcoholic steatohepatitis (NASH), characterized by inflammation and fibrosis, and potentially advancing to cirrhosis or hepatocellular carcinoma [71][72].

The disease is particularly prevalent in developed countries, correlating with rising obesity rates. NAFLD is often asymptomatic in its early stages but can significantly increase liver-related morbidity and mortality as it progresses [73][74]. Lifestyle interventions are currently the cornerstone of managing NAFLD. These interventions primarily focus on achieving weight loss through dietary modifications and increased physical activity. Moderate weight reduction, either via dietary restriction or increased physical activity, is deemed safe and highly recommended [75].

While lifestyle changes remain the first line of treatment, adherence to these recommendations is frequently poor, which has prompted research into novel therapeutic agents aimed at addressing the underlying metabolic disturbances [76]. Current therapeutic strategies being explored include insulin sensitizers, antioxidants, lipid-lowering agents, and other pharmacological interventions, though these have largely been empirical and require further validation through rigorous clinical trials [72][77].

In summary, the development of NAFLD is intricately linked to metabolic dysfunctions, with lifestyle interventions being critical for management. As research progresses, the hope is to establish effective pharmacological treatments that can complement lifestyle modifications in addressing this increasingly prevalent liver disease.

6.2 Pharmacological Treatments ​

Non-alcoholic fatty liver disease (NAFLD) is recognized as the most prevalent chronic liver disease globally, characterized by a complex interplay of pathogenic mechanisms and multifactorial etiology. The development of NAFLD is closely associated with obesity and metabolic syndrome, where various pathophysiological mechanisms contribute to its progression. Key factors include oxidative stress, impaired mitochondrial metabolism, inflammation, dysbiosis of gut microbiota, and the intricate interactions within the brain-liver axis that regulate hepatic lipid metabolism [1][78].

The pathogenesis of NAFLD encompasses several critical processes. These include diet and obesity, insulin resistance, genetic and epigenetic influences, oxidative/nitrosative stress, autophagy dysregulation, hepatic inflammation, and the gut-liver axis involving gut microbes [1]. The accumulation of lipids in the liver leads to steatosis, which can progress to non-alcoholic steatohepatitis (NASH), characterized by inflammation and fibrosis, ultimately resulting in severe liver complications such as cirrhosis and hepatocellular carcinoma [79][80].

Currently, there are no FDA-approved pharmacological treatments specifically for NAFLD. The standard care primarily involves lifestyle modifications, including dietary changes and increased physical activity [79]. However, there is a significant ongoing effort to develop pharmacological therapies targeting various aspects of the disease's pathophysiology. Emerging therapeutic approaches include agents that target peroxisome proliferator-activated receptors (PPARs), glucagon-like peptide-1 (GLP-1) agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and farnesoid X receptor (FXR) agonists [1][78].

In addition to these, drugs like fibroblast growth factor (FGF) analogues, antioxidants, and fatty acid synthase inhibitors (FASNi) are also being explored. These agents aim to modulate pathways involved in lipid metabolism, inflammation, and fibrosis, which are central to the disease's progression [1]. For instance, incretin-based therapies targeting GLP-1 receptors have shown promise in managing NAFLD by enhancing insulin sensitivity and reducing hepatic steatosis [81].

Recent research has highlighted the importance of understanding the relationship between the microbiome, liver metabolism, and systemic inflammation in the context of NAFLD. Probiotics and symbiotics are also being considered as potential therapeutic options due to their ability to influence gut microbiota composition and subsequently impact liver health [78].

In summary, the development of NAFLD is a multifaceted process driven by various metabolic and inflammatory pathways. While lifestyle changes remain the cornerstone of management, emerging pharmacological therapies targeting specific pathophysiological mechanisms hold promise for future treatment strategies aimed at addressing this prevalent liver disease. The ongoing research and clinical trials will likely lead to the establishment of effective therapies for NAFLD and its progressive form, NASH.

6.3 Future Directions in NAFLD Management ​

Non-alcoholic fatty liver disease (NAFLD) is recognized as the most prevalent chronic liver disease globally, characterized by excessive lipid accumulation in hepatocytes. The pathogenesis of NAFLD is complex and multifactorial, involving a variety of metabolic, genetic, and environmental factors. The condition ranges from simple hepatic steatosis (non-alcoholic fatty liver, NAFL) to more severe forms such as non-alcoholic steatohepatitis (NASH), which can progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [82][83].

The development of NAFLD is closely associated with components of the metabolic syndrome, particularly obesity, type 2 diabetes, dyslipidemia, and hypertension. Insulin resistance is considered a primary trigger for the onset of NAFLD, exacerbated by lifestyle factors such as poor diet and sedentary behavior [84][85]. The intricate interplay between these factors leads to hepatic lipid accumulation, inflammation, and fibrosis, thereby complicating the disease progression [78][86].

Current therapeutic approaches for managing NAFLD primarily focus on lifestyle modifications, including weight loss through dietary changes and increased physical activity, which are critical in halting disease progression [75][82]. However, pharmacological treatments are limited, as there are currently no FDA-approved drugs specifically for NAFLD. Existing treatments target various metabolic pathways and aim to alleviate associated conditions, but their efficacy is often modest [82][85].

Emerging therapeutic strategies are increasingly targeting specific pathophysiological mechanisms involved in NAFLD. These include pharmacological agents such as agonists of peroxisome proliferator-activated receptors (PPARs), glucagon-like peptide-1 (GLP-1) agonists, sodium/glucose transport protein 2 (SGLT2) inhibitors, and farnesoid X receptor (FXR) agonists [78][87]. Additionally, therapies targeting inflammation and fibrosis are gaining attention, as chronic low-grade inflammation is a critical component in the progression of NAFLD [21][85].

Future directions in NAFLD management emphasize the need for combination therapies that address multiple pathways simultaneously. The exploration of the gut-liver axis and the microbiome's role in NAFLD pathogenesis presents novel avenues for therapeutic intervention [54][87]. Additionally, advancements in understanding immune response mechanisms in NAFLD could lead to targeted immunomodulatory therapies [21][88].

In summary, the development of NAFLD is a complex interplay of metabolic dysfunctions, with significant contributions from lifestyle factors. Current and emerging therapeutic approaches are beginning to target the underlying mechanisms of the disease, with future strategies likely to focus on combination therapies and novel pathways to improve patient outcomes in this increasingly prevalent condition.

7 Conclusion ​

The findings presented in this review underscore the multifactorial nature of non-alcoholic fatty liver disease (NAFLD), highlighting the intricate interplay between genetic predispositions, environmental factors, and metabolic dysfunctions in its development and progression. Insulin resistance emerges as a central mechanism driving the pathogenesis of NAFLD, leading to lipid accumulation and subsequent inflammation. Furthermore, the role of inflammation, gut microbiota dysbiosis, and hormonal changes significantly contribute to the transition from simple steatosis to more severe liver conditions such as non-alcoholic steatohepatitis (NASH) and fibrosis. The rising prevalence of NAFLD correlates with increasing obesity rates, necessitating a comprehensive approach to prevention and management that includes lifestyle modifications and emerging therapeutic strategies. Future research should focus on elucidating the specific mechanisms underlying NAFLD, exploring combination therapies that target multiple pathways, and investigating the gut-liver axis as a potential therapeutic target. By advancing our understanding of NAFLD, we can improve clinical practices and patient outcomes in this significant public health concern.

References ​

  • [1] Xiaojing Huang;Huiling Chen;Song Wen;Meiyuan Dong;Ligang Zhou;Xinlu Yuan. Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs.. Diabetes, metabolic syndrome and obesity : targets and therapy(IF=3.0). 2023. PMID:37366486. DOI: 10.2147/DMSO.S411400.
  • [2] Arun J Sanyal. An integrated view of liver injury and disease progression in nonalcoholic steatohepatitis.. Hepatology international(IF=6.1). 2013. PMID:26202294. DOI: 10.1007/s12072-013-9479-3.
  • [3] Amina Basha;Sarah C May;Ryan M Anderson;Niharika Samala;Raghavendra G Mirmira. Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models.. International journal of molecular sciences(IF=4.9). 2023. PMID:37373143. DOI: 10.3390/ijms24129996.
  • [4] Hironori Kitade;Guanliang Chen;Yinhua Ni;Tsuguhito Ota. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.. Nutrients(IF=5.0). 2017. PMID:28420094. DOI: 10.3390/nu9040387.
  • [5] Ahmed M Samy;Mohamed A Kandeil;Dina Sabry;A A Abdel-Ghany;Mohamed O Mahmoud. From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences.. Heliyon(IF=3.6). 2024. PMID:38737288. DOI: 10.1016/j.heliyon.2024.e30387.
  • [6] Duarte M S Ferreira;André L Simão;Cecília M P Rodrigues;Rui E Castro. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease.. The FEBS journal(IF=4.2). 2014. PMID:24702768. DOI: 10.1111/febs.12806.
  • [7] Rahim Ullah;Naveed Rauf;Ghulam Nabi;Hamid Ullah;Yi Shen;Yu-Dong Zhou;Junfen Fu. Role of Nutrition in the Pathogenesis and Prevention of Non-alcoholic Fatty Liver Disease: Recent Updates.. International journal of biological sciences(IF=10.0). 2019. PMID:30745819. DOI: 10.7150/ijbs.30121.
  • [8] Mohamed Zaiou;Rim Amrani;Bertrand Rihn;Tahar Hajri. Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease.. Biomedicines(IF=3.9). 2021. PMID:34572442. DOI: 10.3390/biomedicines9091256.
  • [9] Mahmadul Haque;Arun J Sanyal. The metabolic abnormalities associated with non-alcoholic fatty liver disease.. Best practice & research. Clinical gastroenterology(IF=4.0). 2002. PMID:12406441. DOI: 10.1053/bega.2002.0325.
  • [10] Samir Parekh;Frank A Anania. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease.. Gastroenterology(IF=25.1). 2007. PMID:17498512. DOI: 10.1053/j.gastro.2007.03.055.
  • [11] Mohamed Asrih;François R Jornayvaz. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance.. The Journal of endocrinology(IF=3.9). 2013. PMID:23833274. DOI: 10.1530/JOE-13-0201.
  • [12] Qing Liu;Stig Bengmark;Shen Qu. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).. Lipids in health and disease(IF=4.2). 2010. PMID:20426802. DOI: 10.1186/1476-511X-9-42.
  • [13] Melania Gaggini;Mariangela Morelli;Emma Buzzigoli;Ralph A DeFronzo;Elisabetta Bugianesi;Amalia Gastaldelli. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease.. Nutrients(IF=5.0). 2013. PMID:23666091. DOI: 10.3390/nu5051544.
  • [14] E Bugianesi;C Zannoni;E Vanni;R Marzocchi;G Marchesini. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver(IF=3.8). 2004. PMID:15046183. DOI: 10.1016/j.dld.2003.12.008.
  • [15] Ronan Thibaut;Matthew C Gage;Inès Pineda-Torra;Gwladys Chabrier;Nicolas Venteclef;Fawaz Alzaid. Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease.. The FEBS journal(IF=4.2). 2022. PMID:33860630. DOI: 10.1111/febs.15877.
  • [16] Carla Melisa Chackelevicius;Sabrina Eliana Gambaro;Claudio Tiribelli;Natalia Rosso. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.. World journal of gastroenterology(IF=5.4). 2016. PMID:27895397. DOI: 10.3748/wjg.v22.i41.9096.
  • [17] Chong Song;Xian Long;Jianbin He;Yongpan Huang. Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease.. Frontiers in pharmacology(IF=4.8). 2023. PMID:37007030. DOI: 10.3389/fphar.2023.1081334.
  • [18] Moritz Peiseler;Robert Schwabe;Jochen Hampe;Paul Kubes;Mathias Heikenwälder;Frank Tacke. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.. Journal of hepatology(IF=33.0). 2022. PMID:35750137. DOI: 10.1016/j.jhep.2022.06.012.
  • [19] Liu Yang;Yawen Hao;Joost Boeckmans;Robim M Rodrigues;Yong He. Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets.. Pharmacology & therapeutics(IF=12.5). 2023. PMID:36738973. DOI: 10.1016/j.pharmthera.2023.108353.
  • [20] Biki Gupta;Ravi Rai;Michael Oertel;Reben Raeman. Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids.. Seminars in liver disease(IF=3.7). 2022. PMID:35738255. DOI: 10.1055/s-0042-1748037.
  • [21] Nicolás Ortiz-López;Catalina Fuenzalida;María Soledad Dufeu;Araceli Pinto-León;Alejandro Escobar;Jaime Poniachik;Juan Pablo Roblero;Lucía Valenzuela-Pérez;Caroll J Beltrán. The immune response as a therapeutic target in non-alcoholic fatty liver disease.. Frontiers in immunology(IF=5.9). 2022. PMID:36300120. DOI: 10.3389/fimmu.2022.954869.
  • [22] Carolina Vasconcellos;Oureana Ferreira;Marta Filipa Lopes;André Filipe Ribeiro;João Vasques;Catarina Sousa Guerreiro. Nutritional Genomics in Nonalcoholic Fatty Liver Disease.. Biomedicines(IF=3.9). 2023. PMID:36830856. DOI: 10.3390/biomedicines11020319.
  • [23] Silvia Sookoian;Carlos J Pirola. Genetic predisposition in nonalcoholic fatty liver disease.. Clinical and molecular hepatology(IF=16.9). 2017. PMID:28268262. DOI: 10.3350/cmh.2016.0109.
  • [24] Eric Trépo;Luca Valenti. Update on NAFLD genetics: From new variants to the clinic.. Journal of hepatology(IF=33.0). 2020. PMID:32145256. DOI: 10.1016/j.jhep.2020.02.020.
  • [25] Jose M Herranz;Amaya López-Pascual;Alex Clavería-Cabello;Iker Uriarte;M Ujúe Latasa;Ainara Irigaray-Miramon;Elena Adán-Villaescusa;Borja Castelló-Uribe;Bruno Sangro;María Arechederra;Carmen Berasain;Matías A Avila;Maite G Fernández-Barrena. Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD.. Journal of physiology and biochemistry(IF=4.3). 2023. PMID:37620598. DOI: 10.1007/s13105-023-00976-y.
  • [26] Yulei Shi;Wei Qi. Histone Modifications in NAFLD: Mechanisms and Potential Therapy.. International journal of molecular sciences(IF=4.9). 2023. PMID:37834101. DOI: 10.3390/ijms241914653.
  • [27] Jooho Lee;Yuri Kim;Simonetta Friso;Sang-Woon Choi. Epigenetics in non-alcoholic fatty liver disease.. Molecular aspects of medicine(IF=10.3). 2017. PMID:27889327. DOI: 10.1016/j.mam.2016.11.008.
  • [28] Siti Aishah Sulaiman;Vicneswarry Dorairaj;Muhammad Nafiz Haidi Adrus. Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review.. Biomedicines(IF=3.9). 2022. PMID:36672614. DOI: 10.3390/biomedicines11010106.
  • [29] Ioanna Aggeletopoulou;Maria Kalafateli;Efthymios P Tsounis;Christos Triantos. Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease.. International journal of molecular sciences(IF=4.9). 2023. PMID:37629043. DOI: 10.3390/ijms241612864.
  • [30] Seyedeh Kosar Mahmoudi;Shadi Tarzemani;Taha Aghajanzadeh;Mohammadreza Kasravi;Behzad Hatami;Mohammad Reza Zali;Kaveh Baghaei. Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches.. European journal of medical research(IF=3.4). 2024. PMID:38504356. DOI: 10.1186/s40001-024-01708-8.
  • [31] Gary Huang;Daniel F Wallace;Elizabeth E Powell;Tony Rahman;Paul J Clark;V Nathan Subramaniam. Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics.. Biomedicines(IF=3.9). 2023. PMID:37893185. DOI: 10.3390/biomedicines11102809.
  • [32] Meysam Ramezani;Mahsa Zobeiry;Shahrokh Abdolahi;Behzad Hatami;Mohammad Reza Zali;Kaveh Baghaei. A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression.. Pathology, research and practice(IF=3.2). 2023. PMID:37797383. DOI: 10.1016/j.prp.2023.154809.
  • [33] Luisa Bonsembiante;Giovanni Targher;Claudio Maffeis. Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition?. European journal of clinical nutrition(IF=3.3). 2022. PMID:34006994. DOI: 10.1038/s41430-021-00928-z.
  • [34] Clémence Rives;Anne Fougerat;Sandrine Ellero-Simatos;Nicolas Loiseau;Hervé Guillou;Laurence Gamet-Payrastre;Walter Wahli. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.. Biomolecules(IF=4.8). 2020. PMID:33371482. DOI: 10.3390/biom10121702.
  • [35] Arianna Dolce;Sara Della Torre. Sex, Nutrition, and NAFLD: Relevance of Environmental Pollution.. Nutrients(IF=5.0). 2023. PMID:37242221. DOI: 10.3390/nu15102335.
  • [36] Tomas Hrncir;Lucia Hrncirova;Miloslav Kverka;Robert Hromadka;Vladimira Machova;Eva Trckova;Klara Kostovcikova;Pavlina Kralickova;Jan Krejsek;Helena Tlaskalova-Hogenova. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.. Microorganisms(IF=4.2). 2021. PMID:33946843. DOI: 10.3390/microorganisms9050957.
  • [37] Kate Hallsworth;Leon A Adams. Lifestyle modification in NAFLD/NASH: Facts and figures.. JHEP reports : innovation in hepatology(IF=7.5). 2019. PMID:32039399. DOI: 10.1016/j.jhepr.2019.10.008.
  • [38] Catherine J Kerr;Sally P Waterworth;David Brodie;Gavin R H Sandercock;Lee Ingle. The associations between physical activity intensity, cardiorespiratory fitness, and non-alcoholic fatty liver disease.. Journal of gastroenterology and hepatology(IF=3.4). 2021. PMID:34427948. DOI: 10.1111/jgh.15672.
  • [39] Nathan A Johnson;Jacob George. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease.. Hepatology (Baltimore, Md.)(IF=15.8). 2010. PMID:20578153. DOI: 10.1002/hep.23711.
  • [40] Jelena Stevanović;Jorge Beleza;Pedro Coxito;António Ascensão;José Magalhães. Physical exercise and liver "fitness": Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease.. Molecular metabolism(IF=6.6). 2020. PMID:32029220. DOI: 10.1016/j.molmet.2019.11.015.
  • [41] Kim-Anne Lê;Murielle Bortolotti. Role of dietary carbohydrates and macronutrients in the pathogenesis of nonalcoholic fatty liver disease.. Current opinion in clinical nutrition and metabolic care(IF=3.5). 2008. PMID:18542010. DOI: 10.1097/MCO.0b013e328302f3ec.
  • [42] Shira Zelber-Sagi;Justyna Godos;Federico Salomone. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials.. Therapeutic advances in gastroenterology(IF=3.4). 2016. PMID:27134667. DOI: 10.1177/1756283X16638830.
  • [43] Jeremy F L Cobbold;Quentin M Anstee;Simon D Taylor-Robinson. The importance of fatty liver disease in clinical practice.. The Proceedings of the Nutrition Society(IF=4.5). 2010. PMID:20569523. DOI: 10.1017/S0029665110001916.
  • [44] Antonella Mosca;Melania Manco;Maria Rita Braghini;Stefano Cianfarani;Giuseppe Maggiore;Anna Alisi;Andrea Vania. Environment, Endocrine Disruptors, and Fatty Liver Disease Associated with Metabolic Dysfunction (MASLD).. Metabolites(IF=3.7). 2024. PMID:38276306. DOI: 10.3390/metabo14010071.
  • [45] Charles E Foulds;Lindsey S Treviño;Brian York;Cheryl L Walker. Endocrine-disrupting chemicals and fatty liver disease.. Nature reviews. Endocrinology(IF=40.0). 2017. PMID:28524171. DOI: 10.1038/nrendo.2017.42.
  • [46] Huei-Wen Lim;David E Bernstein. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics.. Clinics in liver disease(IF=4.1). 2018. PMID:29128060. DOI: 10.1016/j.cld.2017.08.008.
  • [47] Seema Sharma;Nishant Tiwari;Sampat Singh Tanwar. The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis.. Naunyn-Schmiedeberg's archives of pharmacology(IF=3.1). 2025. PMID:40202676. DOI: 10.1007/s00210-025-04069-z.
  • [48] Meng-Yuan Wu;Jian-Gao Fan. Gut microbiome and nonalcoholic fatty liver disease.. Hepatobiliary & pancreatic diseases international : HBPD INT(IF=4.4). 2023. PMID:37308360. DOI: 10.1016/j.hbpd.2023.06.006.
  • [49] Eunju Park;Jin-Ju Jeong;Sung-Min Won;Satya Priya Sharma;Yoseph Asmelash Gebru;Raja Ganesan;Haripriya Gupta;Ki Tae Suk;Dong Joon Kim. Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.. Cells(IF=5.2). 2021. PMID:34685614. DOI: 10.3390/cells10102634.
  • [50] Sergio Quesada-Vázquez;Gerard Aragonès;Josep M Del Bas;Xavier Escoté. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.. Cells(IF=5.2). 2020. PMID:31936799. DOI: 10.3390/cells9010176.
  • [51] Goran Hauser;Indira Benjak Horvat;Mirjana Rajilić-Stojanović;Irena Krznarić-Zrnić;Michail Kukla;Vedrana Aljinović-Vučić;Ivana Mikolašević. Intestinal Microbiota Modulation by Fecal Microbiota Transplantation in Nonalcoholic Fatty Liver Disease.. Biomedicines(IF=3.9). 2025. PMID:40299326. DOI: 10.3390/biomedicines13040779.
  • [52] Hui Han;Yi Jiang;Mengyu Wang;Mebratu Melaku;Lei Liu;Yong Zhao;Nadia Everaert;Bao Yi;Hongfu Zhang. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis.. Critical reviews in food science and nutrition(IF=8.8). 2023. PMID:34404276. DOI: 10.1080/10408398.2021.1966738.
  • [53] Salvatore Pezzino;Maria Sofia;Gloria Faletra;Chiara Mazzone;Giorgia Litrico;Gaetano La Greca;Saverio Latteri. Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome.. Biology(IF=3.5). 2022. PMID:36358323. DOI: 10.3390/biology11111622.
  • [54] Yun Ji;Yue Yin;Lijun Sun;Weizhen Zhang. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.. International journal of molecular sciences(IF=4.9). 2020. PMID:32357561. DOI: 10.3390/ijms21093066.
  • [55] Lijun Luo;Yongchun Chang;Li Sheng. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.. Life sciences(IF=5.1). 2023. PMID:36965522. DOI: 10.1016/j.lfs.2023.121614.
  • [56] Antonio Gil-Gómez;Paola Brescia;Maria Rescigno;Manuel Romero-Gómez. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.. Seminars in liver disease(IF=3.7). 2021. PMID:34107545. DOI: 10.1055/s-0041-1723752.
  • [57] Marta Maestri;Francesco Santopaolo;Maurizio Pompili;Antonio Gasbarrini;Francesca Romana Ponziani. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies.. Frontiers in nutrition(IF=5.1). 2023. PMID:36875849. DOI: 10.3389/fnut.2023.1110536.
  • [58] Jinping Yin;Yanli Zhu;Rongrong Liu;Weixin Wang;Zhicheng Wang;Jianfeng Wang. A new insight: crosstalk between neutrophil extracellular traps and the gut-liver axis for nonalcoholic fatty liver disease.. Frontiers in immunology(IF=5.9). 2025. PMID:40655142. DOI: 10.3389/fimmu.2025.1599956.
  • [59] Masayoshi Ko;Kenya Kamimura;Takashi Owaki;Takuro Nagoya;Norihiro Sakai;Itsuo Nagayama;Yusuke Niwa;Osamu Shibata;Chiyumi Oda;Shinichi Morita;Atsushi Kimura;Ryosuke Inoue;Toru Setsu;Akira Sakamaki;Takeshi Yokoo;Shuji Terai. Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver.. Disease models & mechanisms(IF=3.3). 2021. PMID:33787507. DOI: 10.1242/dmm.048922.
  • [60] Siwen Shen;Yao Liu;Nuoya Wang;Zhenhe Huang;Guifang Deng. The role of microbiota in nonalcoholic fatty liver disease: mechanism of action and treatment strategy.. Frontiers in microbiology(IF=4.5). 2025. PMID:40809055. DOI: 10.3389/fmicb.2025.1621583.
  • [61] Qi Zhang;Wenmin Xing;Qiao Wang;Zhan Tang;Yazhen Wang;Wenyan Gao. Gut microbiota-mitochondrial inter-talk in non-alcoholic fatty liver disease.. Frontiers in nutrition(IF=5.1). 2022. PMID:36204383. DOI: 10.3389/fnut.2022.934113.
  • [62] Sanja Stojsavljević;Marija Gomerčić Palčić;Lucija Virović Jukić;Lea Smirčić Duvnjak;Marko Duvnjak. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.. World journal of gastroenterology(IF=5.4). 2014. PMID:25561778. DOI: 10.3748/wjg.v20.i48.18070.
  • [63] Chrysoula Boutari;Nikolaos Perakakis;Christos Socrates Mantzoros. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.. Endocrinology and metabolism (Seoul, Korea)(IF=4.2). 2018. PMID:29589386. DOI: 10.3803/EnM.2018.33.1.33.
  • [64] Elaine Hui;Aimin Xu;Hong Bo Yang;Karen S L Lam. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines.. Journal of diabetes investigation(IF=3.0). 2013. PMID:24843689. DOI: 10.1111/jdi.12093.
  • [65] Vera Francisco;Maria Jesus Sanz;José T Real;Patrice Marques;Maurizio Capuozzo;Djedjiga Ait Eldjoudi;Oreste Gualillo. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?. Biology(IF=3.5). 2022. PMID:36009862. DOI: 10.3390/biology11081237.
  • [66] Simona Alexandra Iacob;Diana Gabriela Iacob. Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients - a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown.. Frontiers in endocrinology(IF=4.6). 2022. PMID:35355551. DOI: 10.3389/fendo.2022.814209.
  • [67] Myeong Jun Song;Jong Young Choi. Androgen dysfunction in non-alcoholic fatty liver disease: Role of sex hormone binding globulin.. Frontiers in endocrinology(IF=4.6). 2022. PMID:36482993. DOI: 10.3389/fendo.2022.1053709.
  • [68] Caroline E Geisler;Benjamin J Renquist. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.. The Journal of endocrinology(IF=3.9). 2017. PMID:28428362. DOI: 10.1530/JOE-16-0513.
  • [69] Eleonore Fröhlich;Richard Wahl. Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease.. Metabolites(IF=3.7). 2022. PMID:36005590. DOI: 10.3390/metabo12080718.
  • [70] Dongmei Shi;Jie Chen;Jiaofeng Wang;Jianfeng Yao;Yiqin Huang;Gansheng Zhang;Zhijun Bao. Circadian Clock Genes in the Metabolism of Non-alcoholic Fatty Liver Disease.. Frontiers in physiology(IF=3.4). 2019. PMID:31139087. DOI: 10.3389/fphys.2019.00423.
  • [71] Brent A Neuschwander-Tetri. Non-alcoholic fatty liver disease.. BMC medicine(IF=8.3). 2017. PMID:28241825. DOI: 10.1186/s12916-017-0806-8.
  • [72] Julia Wattacheril;Danny Issa;Arun Sanyal. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.. Annual review of pharmacology and toxicology(IF=13.1). 2018. PMID:29058997. DOI: 10.1146/annurev-pharmtox-010617-052545.
  • [73] Samarth Siddharth Patel;Mohammad Shadab Siddiqui. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease.. Drugs(IF=14.4). 2019. PMID:30588564. DOI: 10.1007/s40265-018-1040-1.
  • [74] Leon A Adams;Paul Angulo;Keith D Lindor. Nonalcoholic fatty liver disease.. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne(IF=11.3). 2005. PMID:15795412. DOI: 10.1503/cmaj.045232.
  • [75] Maria Del Ben;Licia Polimeni;Francesco Baratta;Daniele Pastori;Lorenzo Loffredo;Francesco Angelico. Modern approach to the clinical management of non-alcoholic fatty liver disease.. World journal of gastroenterology(IF=5.4). 2014. PMID:25024593. DOI: 10.3748/wjg.v20.i26.8341.
  • [76] Maria Catalina Hernandez-Rodas;Rodrigo Valenzuela;Luis A Videla. Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease.. International journal of molecular sciences(IF=4.9). 2015. PMID:26512643. DOI: 10.3390/ijms161025168.
  • [77] Danny Issa;Vaishali Patel;Arun J Sanyal. Future therapy for non-alcoholic fatty liver disease.. Liver international : official journal of the International Association for the Study of the Liver(IF=5.2). 2018. PMID:29427492. DOI: 10.1111/liv.13676.
  • [78] Branka Filipovic;Snezana Lukic;Dragana Mijac;Marija Marjanovic-Haljilji;Marko Vojnovic;Jelena Bogdanovic;Tijana Glisic;Natasa Filipovic;Jamal Al Kiswani;Aleksandra Djokovic;Suncica Kapor;Slobodan Kapor;Zoran Bukumiric;Ana Starcevic. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.. International journal of molecular sciences(IF=4.9). 2021. PMID:34948020. DOI: 10.3390/ijms222413219.
  • [79] Chander K Negi;Pavel Babica;Lola Bajard;Julie Bienertova-Vasku;Giovanni Tarantino. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.. Metabolism: clinical and experimental(IF=11.9). 2022. PMID:34740573. DOI: 10.1016/j.metabol.2021.154925.
  • [80] Changyu Zhu;Ira Tabas;Robert F Schwabe;Utpal B Pajvani. Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis.. Nature reviews. Gastroenterology & hepatology(IF=51.0). 2021. PMID:33051603. DOI: 10.1038/s41575-020-00365-6.
  • [81] Alexander J Kovalic;Sanjaya K Satapathy;Naga Chalasani. Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis.. Hepatology international(IF=6.1). 2018. PMID:29600430. DOI: 10.1007/s12072-018-9854-1.
  • [82] Monica A Konerman;Jacob C Jones;Stephen A Harrison. Pharmacotherapy for NASH: Current and emerging.. Journal of hepatology(IF=33.0). 2018. PMID:29122694. DOI: 10.1016/j.jhep.2017.10.015.
  • [83] Herbert Tilg;Alexander R Moschen. Evolving therapies for non-alcoholic steatohepatitis.. Expert opinion on drug discovery(IF=4.9). 2014. PMID:24766298. DOI: 10.1517/17460441.2014.911283.
  • [84] Katelyn Y Graves;Alexandra C H Nowakowski. Childhood Socioeconomic Status and Stress in Late Adulthood: A Longitudinal Approach to Measuring Allostatic Load.. Global pediatric health(IF=1.3). 2017. PMID:29226194. DOI: 10.1177/2333794X17744950.
  • [85] Wanying Geng;Wanying Liao;Xinyuan Cao;Yingyun Yang. Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.. Biomedicines(IF=3.9). 2025. PMID:40002806. DOI: 10.3390/biomedicines13020393.
  • [86] Jia Wang;Lei Wang;Xiao-Jing Zhang;Peng Zhang;Jingjing Cai;Zhi-Gang She;Hongliang Li. Recent updates on targeting the molecular mediators of NAFLD.. Journal of molecular medicine (Berlin, Germany)(IF=4.2). 2023. PMID:36792729. DOI: 10.1007/s00109-022-02282-4.
  • [87] Li Rong;Junyan Zou;Wei Ran;Xiaohong Qi;Yaokai Chen;Hongjuan Cui;Jinjun Guo. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).. Frontiers in endocrinology(IF=4.6). 2022. PMID:36726464. DOI: 10.3389/fendo.2022.1087260.
  • [88] Ziwei Guo;Qinjuan Wu;Pengfei Xie;Jiuchong Wang;Wenliang Lv. Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications.. Frontiers in immunology(IF=5.9). 2024. PMID:38352880. DOI: 10.3389/fimmu.2024.1336493.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Non-alcoholic fatty liver disease · Insulin resistance · Metabolic syndrome · Gut microbiota · Inflammation

© 2025 MaltSci